Part 1, Advancing Biomarker-Drive...
Part 1, Advancing Biomarker-Driven Care Through Optimized IHC Testing: Practical Insights on IHC Testing Across Tumor Types

FLASCO OncoPod by Florida Society of Clinical Oncology

Episode notes

In this episode of the FLASCO OncoPod, host Dr. Edgardo Santos, President of the Florida Society of Clinical Oncology (FLASCO), leads a multidisciplinary discussion on the evolving role of immunohistochemistry (IHC) in precision oncology. Joined by Dr. Lamees Saeed (Tampa General Hospital Cancer Institute), Dr. Jesus Fabregas (Memorial Cancer Institute), Dr. Ana Sandoval (Herbert Wertheim Cancer Institute at Baptist Health South Florida), and Dr. Nathalie McKenzie (AdventHealth Cancer Institute), the panel explores how IHC has evolved from a diagnostic tool into a critical component of biomarker-driven treatment selection.

The conversation highlights how IHC is shaping clinical decision-making across breast, gastrointestinal, gynecologic, and thoraci ... 

Read more
Keywords
oncologycancerhealthcareImmunotherapybreastcancerEndometrial CancerIHC Testing